Provided is a cell culture test device including a plurality of well units. Each of the well units includes an inlet portion through which a first fluid and a second fluid are introduced and a bottom portion including a first sub-well in which the first fluid is accommodated. A first stepped portion protrudes toward the center of the well unit along the circumference of the inner wall of the well unit such that the well unit has a lower portion whose inner width is smaller than that of an upper portion at the inlet portion side.

Provided is a cell culture test device including a plurality of well units. Each of the well units includes an inlet portion through which a first fluid and a second fluid are introduced and a bottom portion including a first sub-well in which the first fluid is accommodated. A first stepped portion protrudes toward the center of the well unit along the circumference of the inner wall of the well unit such that the well unit has a lower portion whose inner width is smaller than that of an upper portion at the inlet portion side.

The present invention relates to a method for assessing cell viability of bacterial and fungal cells and to a method for the detection of bacterial and fungal cells with specific enzyme activities. The methods of the present invention rely on the real-time measurement of the level of luminescence signal from a luciferase enzyme directly from a growing culture of bacterial or fungal cells. Furthermore, the present invention relates to a method for assessing susceptibility of bacterial cells to antibiotics by measuring ATP levels using a luciferase assay system.

The present invention relates to a method for assessing cell viability of bacterial and fungal cells and to a method for the detection of bacterial and fungal cells with specific enzyme activities. The methods of the present invention rely on the real-time measurement of the level of luminescence signal from a luciferase enzyme directly from a growing culture of bacterial or fungal cells. Furthermore, the present invention relates to a method for assessing susceptibility of bacterial cells to antibiotics by measuring ATP levels using a luciferase assay system.

A cell population (55) is cultured on a cell culture substrate (50) while agents contained in agent reservoirs (31, 33, 35) at predefined positions in a culture container (10) diffuse through the substrate (50) and form at least partly overlapping concentration gradients in the substrate (50) within combination areas (41, 43, 45) and substantially non-overlapping concentration gradients in the substrate (50) peripheral to an outer boundary of the agent reservoirs (31, 33, 35). Inhibition end points (61, 63, 65) of respective inhibition zones (60, 62, 64) substantially lacking any growth of the cell population (55) peripheral to the outer boundary of the agent reservoirs (31, 33, 35) and growth end points (71, 73, 75) of respective growth zones (70, 72, 74) comprising growth of the cell population (55) within the combination areas (41, 43, 45) are determined and used to determine interaction effects between the agents on the cell population (55).

A cell population (55) is cultured on a cell culture substrate (50) while agents contained in agent reservoirs (31, 33, 35) at predefined positions in a culture container (10) diffuse through the substrate (50) and form at least partly overlapping concentration gradients in the substrate (50) within combination areas (41, 43, 45) and substantially non-overlapping concentration gradients in the substrate (50) peripheral to an outer boundary of the agent reservoirs (31, 33, 35). Inhibition end points (61, 63, 65) of respective inhibition zones (60, 62, 64) substantially lacking any growth of the cell population (55) peripheral to the outer boundary of the agent reservoirs (31, 33, 35) and growth end points (71, 73, 75) of respective growth zones (70, 72, 74) comprising growth of the cell population (55) within the combination areas (41, 43, 45) are determined and used to determine interaction effects between the agents on the cell population (55).

Methods for identifying and providing therapeutic solutions for treating polymicrobial infections, such as but not limited to urinary tract infections, based on concordance between ABR genes and antibiotic susceptibility. The methods herein feature detection and identification of organisms of the polymicrobial infection, phenotypic pooled sensitivity tests for determining the susceptibility or resistance of the polymicrobial infection in the sample to an antibiotic or other therapeutic agent, and identification of resistance genes, e.g., genetic markers that may indicate resistance to a particular treatment. Together, the data can be applied against databases of antibiotic/therapeutic susceptibility or resistance for particular known polymicrobial infections in order to provide one or more therapeutic solutions for the polymicrobial infection.

A method for determining an interaction between a medicament and a cell type comprising an array of first microdroplets, each containing a cell type derived from a biological sample, an array of second microdroplets, each containing one or more medicaments at one or more predetermined concentrations, merging the array of first microdroplets and the array of second microdroplets to form an array of merged microdroplets, and monitoring the characteristics of one or more cells in the merged microdroplets using an optical detection system configured to detect an interaction between a cell type and a medicament.

A method for determining an interaction between a medicament and a cell type comprising an array of first microdroplets, each containing a cell type derived from a biological sample, an array of second microdroplets, each containing one or more medicaments at one or more predetermined concentrations, merging the array of first microdroplets and the array of second microdroplets to form an array of merged microdroplets, and monitoring the characteristics of one or more cells in the merged microdroplets using an optical detection system configured to detect an interaction between a cell type and a medicament.

An exemplary embodiment of the present disclosure provides a system for detecting antimicrobial resistance of a bacteria in a biological sample. In some embodiments, the system can include a plurality of containers, a detecting agent in each of the plurality of containers, and an antimicrobial agent in at least a portion of the plurality of containers. The antimicrobial agent is disposed in at least one of the plurality of containers. Each of the containers can contain at least a portion of the biological sample. The detecting agent can be configured to produce optically detectable changes responsive to bacterial respiration or growth, directly from patient samples of from patient sample cultures.